| Document |
Document Title |
|
WO/2024/153137A1 |
Provided in the present invention is a method for preparing chiral amino alcohol pharmaceutical intermediates as represented by formula A and formula A2 or salts thereof. Compared with a chiral resolution preparation method in the prior ...
|
|
WO/2024/153225A1 |
The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directe...
|
|
WO/2024/146621A1 |
The present invention relates to a method of preparing glufosinate or a derivative thereof.
|
|
WO/2024/140776A1 |
Disclosed in the present invention are a preparation method for a stereoisomer and an intermediate thereof, and a preparation method for and the use of the intermediate, in particular the use thereof in the preparation of an active compo...
|
|
WO/2024/142909A1 |
This compound is represented by general formula (M1). In formula (M1), Y is a linear or branched C1-C10 alkyl group, a polymerizable group-containing group, or a group represented by [SiX3-Y11-*]. Y11 is a linear or branched C1-C4 alkyle...
|
|
WO/2024/139061A1 |
A method for synthesizing amide and/or a polypeptide with an unprotected amino acid as an amine component. The method for preparing the polypeptide comprises using an amino acid or a peptide fragment, which has unprotected amino and carb...
|
|
WO/2024/140870A1 |
Disclosed is a method for splitting a ramipril intermediate, belonging to the field of pharmaceutical chemicals. The method involves preparing a crystal of the chemical compound of formula (I) so as to split a ramipril intermediate, the ...
|
|
WO/2024/127829A1 |
A phenoxycarbamoyl chloride compound useful as an intermediate for the production of a phenoxyurea compound having an insecticidal activity, an acaricidal activity and/or a nematicidal activity is represented by formula (1) (wherein R1 r...
|
|
WO/2024/124357A1 |
A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (...
|
|
WO/2024/113392A1 |
Disclosed in the present invention is a method for synthesizing a primary intermediate of a hair dye. The method comprises: starting from a 2-hydroxy-5-nitroacetophenone compound, and subjecting same to carbonyl reduction and nitro reduc...
|
|
WO/2024/118602A1 |
Provided herein are formulations comprising a plurality of lipid particles in a liquid mixture, wherein each lipid particle comprises one or more phospholipids, or a pharmaceutically acceptable salt thereof, and a first T-cell immunoglob...
|
|
WO/2024/114811A1 |
Provided are a compound and a use thereof in treatment of Treg-related diseases, in particular, a use thereof in contributing to prevention and/or treatment of diseases prevented or treated by the compound by increasing the quantity of T...
|
|
WO/2024/110994A1 |
The present disclosure relates to process for the preparation of Ledipasvir (I) or of its pharmaceutically acceptable salts. The present disclosure also provides novel intermediates (IV–XI) that are used in the synthesis of Ledipasvir....
|
|
WO/2024/109817A1 |
Purification process for conjugate (S) -3- ( ( ( (S) -1- ( (S) -2- (6-methoxynaphthalen-2-yl) propanoyloxy) ethoxy) carbonyl-amino) methyl) -5-methylhexanoic acid is described herein.
|
|
WO/2024/109665A1 |
The present invention belongs to the field of biomedicines. Disclosed are carbamate-bond-containing lipid compounds and the use thereof. The lipid compounds are compounds of the following structure, the definition of each group being as ...
|
|
WO/2024/108311A1 |
A method of assessing a risk of developing Alzheimer's disease (AD) and of diagnosing AD in a subject comprising: comparing a level of extracellular vesicles (EVs) that are positive for at least one biomarker in a biofluid sample taken f...
|
|
WO/2024/102404A1 |
The subject matter described herein is directed to methods of preparing compounds of general Formula I: or a salt or solvate thereof.
|
|
WO/2024/094526A1 |
The present invention relates to 6-diazo-5-oxo-L-norleucine prodrugs having reduced toxicity and increased tumor specificity and to their therapeutic use for treating cancer.
|
|
WO/2024/094125A1 |
Provided herein are lipid compounds, e.g., a compound of Formula (I). Also provided are lipid nanoparticles and pharmaceutical compositions, each comprising a lipid compound, e.g., a compound of Formula (I).
|
|
WO/2024/094961A1 |
The present invention relates to a method of producing a moisture-cure resin composition, the method comprising the steps of: preparing a hydroxy alkyl urethane modifier having the formula:(I); where: R1 is an amine residue; and R2 and R...
|
|
WO/2024/092892A1 |
Provided are an edoxaban intermediate and a preparation method therefor. Specifically, the edoxaban intermediate includes intermediate compounds of formula I and formula II. The preparation method comprises: subjecting a compound of form...
|
|
WO/2024/089159A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, pharmaceutical compositions comprising the compounds and methods for synthesising compounds according to formula I. This invention further...
|
|
WO/2024/091450A1 |
The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
|
|
WO/2024/089666A1 |
An efficient, economical and continuous process for the preparation of L-lysine-D- amphetamine dimesylate.
|
|
WO/2024/085208A1 |
This compound is a compound represented by formula (1). [In the formula, n represents an integer from 1-3. L1 represents a possibly branched, (n + 1)-valent linking group (but excluding chain saturated aliphatic hydrocarbon groups). ...
|
|
WO/2024/075760A1 |
The present invention addresses the problem of providing: a novel method for producing a N-acetyl-D-galactosamine ligand-oligonucleotide conjugate, particularly a novel method for producing a N-acetyl-D-galactosamine unit; and a novel in...
|
|
WO/2024/075535A1 |
In the present invention, there is employed a resist composition having, as a base resin, a polymer compound that has constituent units derived from a compound expressed by general formula (a0−m). In the formula, W is a polymerizable-g...
|
|
WO/2024/071178A1 |
Provided is an industrially useful method for producing an alkylsilyloxy-substituted benzylamine compound, in which impurities are easily removed and the method does not involve an alkylsilyloxy-substituted benzyl compound that is an int...
|
|
WO/2024/056678A1 |
The present invention relates to compounds according to formula (I), which are prodrugs of the psychoactive compound phenethylamine or its derivatives. The prodrugs provided herein exhibit improved pharmacokinetic properties during uptak...
|
|
WO/2024/053494A1 |
This (meth)acrylic group-containing polycarboxylic acid compound is represented by general formula (1) and/or general formula (2). R1 and R3 denote alkylene groups. R2 denotes a single bond or an alkylene group. R4 denotes an alkylene gr...
|
|
WO/2024/053350A1 |
The purpose of the present invention is to provide a method for producing an aminoazide compound and a diamine compound in which the formation of undesired diastereomers is inhibited and which has good diastereoselectivity. Provided is a...
|
|
WO/2024/054321A1 |
Non-triazole compounds are provided that can be effective to inhibit corrosion of a corrodible metal surface in an aqueous system. The non-triazole compounds show comparable or better corrosion inhibition as compared to conventional tria...
|
|
WO/2024/046279A1 |
The present invention relates to a compound of formula (I), which has a plurality of crystal forms. The crystal forms of the compound show good stability in addition to higher purity, especially crystal form I, crystal form II and crysta...
|
|
WO/2024/044728A1 |
The present disclosure relates to PEGylated lipid compounds and pharmaceutically acceptable salts thereof. Such compounds are useful, for example, as constituent parts of lipid nanoparticle (LNP) formulations for delivery of various acti...
|
|
WO/2024/024965A1 |
The present invention addresses the problem of providing a method for producing an O-substituted serine derivative, which makes it possible to produce an O-substituted serine derivative in fewer steps. The present inventors have made ext...
|
|
WO/2024/019936A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2024/011415A1 |
Disclosed in the present invention is a method for preparing an o-iodophenyl compound, wherein an iodobenzene compound and an amide compound as raw materials are reacted in the presence of sodium hydride or n-butyllithium and a solvent t...
|
|
WO/2024/012565A1 |
The present invention provides a memantine derivative or a stereoisomer, solvate or pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a use in preparing a drug for preventing and/or treating central nerv...
|
|
WO/2024/012397A1 |
The present invention relates to a compound having a structure represented by formula I, formula II, formula III, formula IV, formula V or formula VI, or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical compos...
|
|
WO/2024/007851A1 |
A catalyst for amide synthesis and preparation and use thereof are disclosed. The catalyst is a thio or seleno pyranodipyrimidine compound and has a simple and novel structure, high catalytic efficiency, and good atom economy. The cataly...
|
|
WO/2023/233164A1 |
Compounds of formula (I) wherein R1, R2 and R3 are as defined herein are able to rescue dysfunctional mitochondria and are therefore of use in the treatment and prevention of neurodegenerative disorders as well as acute radiation syndrom...
|
|
WO/2023/227757A1 |
The invention provides protected ortho-quinone compounds comprising a group represented by: Formula (I) where -Ar- is optionally substituted phenylene, -X is selected from -NH2, -OH and -SH, and the protected forms of each, -W- is option...
|
|
WO/2023/222870A1 |
The present invention generally relates to the field of ionizable (also termed cationic) lipids,and in particular provides a novel type of such lipids as represented by any of the formulae disclosed herein. The present invention further ...
|
|
WO/2023/219152A1 |
One aspect of the present invention relates to a method for producing a salt of an amino acid, a salt of a peptide compound, or a solvate of either one of the salts, the method comprising the following steps (A) and (B). Step (A): a st...
|
|
WO/2023/208020A1 |
Disclosed are an intermediate of a polyamine derivative pharmaceutical salt, a preparation method therefor, and use thereof. The intermediate compound has the following structure: (I), which can be used to prepare a polyamine derivative ...
|
|
WO/2023/206874A1 |
A sacubitril intermediate, a preparation method therefor, and use thereof. A key intermediate N-Boc amino alcohol represented by formula (10) or formula (10-a) can be efficiently prepared. The intermediate can be used to prepare a neutra...
|
|
WO/2023/203254A2 |
The present invention relates to compounds inhibiting the toxic activity of extrasynaptic NMDA receptors, in particular by inhibiting the formation of NMDA receptor/TRPM4 complexes. In particular, the present invention relates to diamine...
|
|
WO/2023/205237A1 |
Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are...
|
|
WO/2023/200913A1 |
Described herein are methods of synthesizing 5-chloro-2-((ethoxycarbonyl)amino)-3- methylbenzoic acid and derivatives thereof.
|
|
WO/2023/196444A1 |
Ionizable cationic lipids, methods for synthesizing them, as well as intermediates useful in synthesis of these lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component o...
|
